BrachyDOSE is thrilled to announce that it has successfully raised $554,000 in its latest funding round. This notable investment marks a significant milestone for a company that is rapidly transforming the landscape of cancer treatment. BrachyDOSE is not just another tech company—it is a game-changing cancer treatment quality control tool designed to empower oncology doctors to deliver 100% accurate and error-free radiotherapy treatments. By merging advanced hardware dose measurement tools with innovative deep learning algorithms, BrachyDOSE offers a revolutionary approach that addresses critical challenges affecting over 200 million patients worldwide across more than 2,000 hospitals in both Europe and the USA.
The fresh capital infusion will accelerate the company’s mission to equip medical professionals with cutting-edge, safe, and highly effective solutions. It is strategically earmarked to optimize the development of their proprietary system, which not only enhances treatment accuracy but also has the potential to reduce overall patient treatment costs by three to five times. Moreover, the technology is expected to save up to 50% of the time that doctors and medical specialists currently spend on procedure preparation, enabling them to focus more on patient care and hasten the journey of cancer patients back to normal life. With a core set of values centered on quality, innovation, and partnership, and a vision to empower every hospital in the world to combat cancer effectively, this funding round sets the stage for a new era in radiotherapy treatment that promises improved outcomes and enhanced quality control in every patient interaction.
